Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
Clin Cancer Res. 2019 Oct 15;25(20):6015-6017. doi: 10.1158/1078-0432.CCR-19-1986. Epub 2019 Jul 19.
A multitude of regulatory approvals has recently changed the therapeutic landscape of acute myeloid leukemia. Among these was upfront therapy with the Hedgehog inhibitor glasdegib with low-dose cytarabine. Understanding the process of and rationale for approval of this promising combination is timely and valuable for the oncology community..
近期，大量的监管审批改变了急性髓系白血病的治疗格局。其中包括用 Hedgehog 抑制剂 glasdegib 联合低剂量阿糖胞苷进行一线治疗。了解这种有前途的联合用药的审批过程和原理对肿瘤学界来说是及时且有价值的。
